Navigation Links
New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
Date:5/9/2011

CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population.  The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in 73 percent of patients aged 6-17 years at week 8, the primary endpoint of the trial.  REMICADE received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active UC in September 2005 and in October 2006, REMICADE received FDA approval for maintaining clinical remission and mucosal healing indications in adults living with UC.

UC is a chronic inflammatory bowel disease (IBD) of the colon.  It is estimated that 1.4 million Americans have IBD with the number evenly split between UC and Crohn's disease.  An estimated 150,000 children under age 17 are living with debilitating symptoms of IBD.(1)  

"The results of this study are consistent with findings from the Active Ulcerative Colitis (ACT) trials, which evaluated REMICADE in the treatment of adults with ulcerative colitis," said Jeffrey Hyams, Head of the Division of Digestive Diseases and Nutrition at Connecticut Children's Medical Center and Professor of Pediatrics at University of Connecticut School of Medicine, and lead study investigator.  "UC can be a devastating disease, particularly for children and adolescents.  It is encouraging to see such promising results in a patient population that is in need of additional treatment options."

In December 2010, Centocor Ortho Biotech Inc. submitted a supplemental Biologics License Application (sBLA) to the FDA requesting the approval of REMICADE (infliximab) for the treatment of modera
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... and CEO Marc Hedrick , M.D. will present live ... Thursday, December 4, 2014 TIME:    11:15 am PT ... or paste this URL into your browser,s address bar: ... to save time and receive event updates. ...
(Date:11/18/2014)... November 17, 2014 RPS Diagnostics ... tests – today announces its third annual partnership ... (CDC) Get Smart About Antibiotics Week from November ... a national campaign designed to highlight the coordinated ... and non-profit and for-profit partners to provide education ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
(Date:11/18/2014)... Brothers Josh and Bryce Benbasat (ages 15 ... Curing Cancer, Inc . in recognition of National Pet ... is dedicated to raising funds for pet cancer research. ... University of Florida College of Veterinary Medicine . “We ... the recipient of this vital funding. It will be ...
Breaking Biology Technology:Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today ... up to $185 million in exchange for rights ... American sales of Lexiscan(TM),(regadenoson) injection. CV Therapeutics received ... receive a potential future milestone payment,of $10 million., ...
... and Families, EMERYVILLE, Calif., April 15 ... two new health care areas designed to,soothe patients ... to offer health resources. The Carol Ann,Read Breast ... procedures, all in one location, for the quickest ...
... April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, ... Dr. Anders,Kolb of the Nemours Center for Childhood ... Pediatric Sarcomas" was,presented today at the American Association ... being held in San Diego, California from,April 12-16, ...
Cached Biology Technology:CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
(Date:11/4/2014)... 2014   Neurotechnology , a provider of ... latest version of its fingerprint matching algorithm has ... evaluation organized by NIST. The MINEX test ... INCITS 378 fingerprint standard template format. MINEX compliance ... in the United States ...
(Date:11/3/2014)... A University of Colorado Cancer Center study ... Academy of Sciences describes the activity of a ... Interleukin 37 or IL-37. It has been known to ... in the adaptive immune system: IL-37 inhibits the ability ... antigens. , "Knowing this mechanism that underlies IL-37,s effect ...
(Date:11/3/2014)... low birth weight and preterm birth are linked to ... Findings published in the American College of Rheumatology (ACR) ... low birth weight and pre-term babies were not at ... adults. , According to the ACR, 27 million ... clinical OA. Symptoms of OA range from mild to ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... 1, 2008) As gas prices continue to soar to ... that wont cramp their pocketbooks. Scientists at U.S. ... call by working to chemically manipulate algae for production ... gas. We believe there is a fundamental advantage ...
... New Rochelle, NY, April 1, 2008Biotechnology companies are ... overcome the limitations of current diagnostic tests for ... To effectively move cancer therapy forward, a much ... required, according to an article in the April ...
... available in French . </P , Paleontologists from the ... presence of 356 animal inclusions in completely opaque amber from ... of the European light source to image two kilogrammes of ... survey of large amounts of opaque amber. At present this ...
Cached Biology News:Algae could one day be major hydrogen fuel source 2Scientists discover 356 animal inclusions trapped in 100 million years old opaque amber 2
... Description: Proteinase K is a ... wide range of applications purified from the fungus ... the carboxyl group of N-substituted hydrophobic aliphatic and ... as a serine protease. Proteinase K is useful ...
... high throughput, water bath thermal cycler capable of ... This equates to 9,216 reactions per run when ... transfers a basket of plates between three water ... considerably faster than those of peltier block cyclers. ...
... Dideoxycytidine Dideoxycytidine is a cytidine analog that ... retroviral activity. Immunogen: Chemical / ... The specificity of the ddC antiserum was ... of ddC to moles of ddC analog at ...
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
Biology Products: